Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Down 8.90%
As of Wednesday, July 22, Damora Therapeutics, Inc.’s DMRA share price has dipped by 8.90%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Up 5.75%
As of Monday, July 20, Damora Therapeutics, Inc.’s DMRA share price has surged by 5.75%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Up 7.43%
As of Tuesday, July 14, Damora Therapeutics, Inc.’s DMRA share price has surged by 7.43%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Down 6.24%
As of Monday, July 13, Damora Therapeutics, Inc.’s DMRA share price has dipped by 6.24%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Damora Therapeutics, Inc.’s (DMRA) Stock Is Up 6.41%
As of Thursday, July 09, Damora Therapeutics, Inc.’s DMRA share price has surged by 6.41%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,798.0 | $251.9 | 52% |
|
| Shares Out (Mil) | 34.3 | 50.8 | 40% |
|
| Institutional Ownership | 99.7% | 92.0% | 93% |
|
| Float (Mil) | 41.2 | 40.5 | 43% |
|
| Beta | 1.51 | 0.95 | 83% |
|
| Avg Daily Volume (000s) | 443 | 447 | 57% |
|
| Price Change (52-week) |
713.7% | 54.2% | 100% |
|
| Growth | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | (43.2%) | (9.8%) | 8% |
|
| EPS (5yr) | 4.2% | 16.3% | 37 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (26.5%) | (15.6%) | 23% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.370) | ($1.755) | ($2.078) | |
| Month Ago EPS | ($0.370) | ($1.755) | ($2.078) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.510) | ($2.350) | ($2.440) | |
| Year/Year Chg | (54.3%) | (98.9%) | (98.4%) | |
| Financials | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($235) | ($43) | 6% |
|
| EPS (TTM) | ($24.470) | ($1.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($25) | ($30) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1,151 | $182 | 43% |
|
| Valuation | DMRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.64 | 2.60 | 76% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | DMRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (85.4%) | (49.7%) | 7% |
|
| ROE | (120.1%) | (55.4%) | 8% |
|
| Liabilities to Assets | 4.5% | 30.3% | 2% |
|
| F-Score | 3 | 3 | 19% |
|
Damora Therapeutics, Inc. did not pass any screens on 7/30/2026.
